Skip to content

A Message To Our Clients

A Message To Our Clients

To Our Clients,


First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service that you have become accustomed to.  If you have any questions regarding our Business Continuation Plan, please reach out to info@arfinnmed.com.


We understand that routines will be temporarily changed in the coming months, so we are adapting to accommodate this change.  This means building out a more robust telemedicine system, increasing our patient portal functionality,  generating consents to be e-signed, and streamlining our patient intake process to cut down on wait times.  


As we settle into new workflows and challenges, we will suspend all monthly fees for using Arfinn Med until June 1st.  We also will activate our full suite of functionality to all current users so you are able to offer the best care to patients in the interim.  We know this doesn’t seem like much in these times, but we want to show our gratitude to the medical professionals who are on the front lines helping patients get the help they desperately need.  If you haven’t already, you will be seeing these updates on your account over the weekend. 


Please stay safe, and let us know if you require anything to continue running your practices.  I have set aside a development team to continually assess how to improve care and keep stakeholders safe.
Sincerely, 


James West CEO

Stories you may be interested in

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More

DeSantis OKs telehealth for Florida medical marijuana patients

TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Leave a Comment

You must be logged in to post a comment.